Experience the unique Unconference format, where you wield the power to shape sessions based on your interests. Dive into participant-driven discussions, ignite collaborations, and innovate within an open, dynamic environment.
Be at the forefront of the agenda-setting process, fostering an engaging and personalised experience.
The Unconference Sessions will be in the form of an open theatre presentation in the exhibition, accessible to all registered participants.
This format allows any delegate and industry member to take the podium and share ideas, trends, and expertise.
Unconference Session:
Company: Tarsus Pharmaceuticals Inc.
Date and Time: 6 March, 15:15 – 15:35
Speaker: Erik L. Mertens
Title: Demodex Blepharitis Impact on Eye Health
Demodex blepharitis (DB) is a common, often overlooked eyelid margin disease that may compromise ocular surface stability and visual quality. This session highlights the importance of recognizing and managing DB, especially in patients undergoing refractive surgery. Early detection, with attention to collarettes, is key to protecting lid and ocular surface health.
Unconference Session:
Company: Ophtec BV
Date and Time: 6 March, 12:00 – 12:20
Speaker: Prof. José Luis Güell
Title: Bridging the Presbyopia Treatment Gap: Artiplus Multifocal Phakic IOL for Young Presbyopes
Presbyopia remains one of the fastest-growing unmet needs in refractive surgery, particularly among younger, active patients who seek spectacle independence while preserving their natural ocular anatomy. Despite advances in presbyopia correction, a clear treatment gap persists for this demanding patient group. The Artiplus multifocal phakic intraocular lens has been specifically designed to address this gap, offering a novel surgical solution for young presbyopes with healthy eyes and high visual expectations.
In this session, Prof. José Luis Güell will provide a comprehensive overview of the Artiplus IOL as a tailored solution for presbyopia correction, highlighting its unique design, clinical rationale, and positioning within today’s presbyopia correction landscape. The presentation will focus on ideal candidate profiles, key clinical benefits, and expected visual performance, supported by clinical data and real-world case experiences. Attendees will gain practical guidance on how Artiplus can expand their treatment portfolio and meet the evolving demands of modern presbyopic patients.